Plain-English translation of NCT06999694 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether combining proton radiotherapy (a highly precise form of radiation) with two immunotherapy medications called and can help people with hepatocellular carcinoma (a type of liver cancer) that cannot be surgically removed. and are already approved medications for this cancer, but when used alone they only work for about 1 in 5 patients. Early research suggests that combining this medication with radiation therapy may help more patients respond to treatment.
The two immunotherapy drugs work well for some patients but not others, with response rates around 20%. Early evidence suggests that adding precise radiation therapy to the treatment may boost the body's immune response against the cancer and significantly improve how many patients benefit from this medication.
You likely qualify if…
You likely don't qualify if…
Participants in this trial will receive proton radiotherapy targeted at their liver cancer combined with infusions or injections of the two immunotherapy medications over a treatment period. The exact schedule of visits and treatment sessions would be determined by the research team, typically involving multiple appointments at the hospital or clinic for radiation sessions and medication administration. Throughout the trial, you would have regular blood tests and imaging scans to monitor how well the treatment is working and to watch for any side effects.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
Taiwan